Table 3.

Reported outcomes for patients presenting with solitary plasmacytoma

Author		N	Local recurrence, %	Overall survival, % (years)	Progression-free survival, % (years)
Nahi et al. [4]	Total	191	NR	53% (8 years)	75% (2 years)
	SBP	124	NR	56% (8 years)	65% (2 years)
	EMP	67	NR	51% (8 years)	94% (2 years)
De Waal et al. [36]	Total	100	0%	68% (10 years)	50% (15 years)
	SBP	66	0%	64%(10 years)	30% (15 years)
	EMP	34	0%	77% (10 years)	88% (15 years)
Katodritou et al. [61]	Total	97	NR	78% (10 years)	59% (10 years)
	SBP	65	NR	69% (10 years)	40% (10 years)
	EMP	32	NR	86% (10 years)	50% (10 years)
Reed et al. [48]	Total	84	8%	78% (5 years)	47% (5 years)
	SBP	59	3%	76% (5 years)	56% (5 years)
	EMP	25	20%	85% (5 years)	30% (5 years)
Kilciksiz et al. [45]	Total	80	6%	73% (10 years)	NR
	SBP	57	6%	68% (10 years)	NR
	EMP	23	5%	89% (10 years)	NR
Ozsahin et al. [5]	Total	258	14%	55% (10 years)	35% (10 years)
	SBP	206	14%	52% (10 years)	28% (10 years)
	EMP	52	14%	72%(10 years)	74% (10 years)
Tsang et al. [47]	Total	46	17%	65% (8 years)	50% (8 years)
	SBP	32	22%	NR	36% (8 years)
	EMP	14	7%	NR	84% (8 years)
Liebross et al. [24]	SBP	57	4%	50% (10 years)	47% (10 years)
Liebross et al. [3]	EMP	22	7%	50% (10 years)	68% (10 years)

NR not reported, SBP solitary bone plasmacytoma, EMP extramedullary plasmacytoma